Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: Clin Cancer Res. 2016 Dec 29;23(14):3734–3743. doi: 10.1158/1078-0432.CCR-16-1446

Figure 5. Comparison of ibrutinib and acalabrutinib-mediated changes in the levels of Bcl-2 and Mcl-1 antiapoptotic proteins.

Figure 5

A. CLL cells were incubated with DMSO only (controls) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours without IgM stimulation (lanes 1-5) or with IgM stimulation (lanes 6-10). The protein lysates were immunoblotted for total Bcl-2 and Mcl-1 proteins. Vinculin was used as a loading control. B-C. Immunoblots were analyzed from five different patients, and changes in Mcl-1 and Bcl-2 in CLL cells treated with BTK inhibitors without (B) or with (C) IgM stimulation were quantitated. Values represent fold change relative to DMSO controls.